

CLAIMS

1. A therapeutic agent for inhibiting vascularization comprising as the effective ingredient, a substance that inhibits the action due to CXCR4.

2. A therapeutic agent for a solid cancer comprising as the effective ingredient, a substance that inhibits the action due to CXCR4.

3. A therapeutic agent for a disease pathologically caused by neovascularization comprising as the effective ingredient, a substance that inhibits the action due to CXCR4.

4. A therapeutic agent for repairing a tissue comprising as the effective ingredient, a substance that inhibits the action due to CXCR4.

5. The therapeutic agent according to ^{Claim 1} ~~any of~~ ~~claims 1-4~~, wherein the substance inhibits the ~~very~~ binding between SDF-1 and CXCR4.

6. The therapeutic agent according to ^{Claim 1} ~~any of~~ ~~claims 1-4~~, wherein the substance inhibits signaling from CXCR4 to nuclei.

7. The therapeutic agent according to ^{Claim 1} ~~any of~~ ~~claims 1-4~~, wherein the substance inhibits the ~~very~~ expression of CXCR4.

8. The therapeutic agent according to ^{Claim 1} ~~any of~~ ~~claims 1-4~~, wherein the substance inhibits the ~~very~~ expression of SDF-1.

9. The therapeutic agent according to claim 5, wherein the substance inhibits SDF-1.

10. The therapeutic agent according to claim 5, wherein the substance inhibits CXCR4.

5 11. The therapeutic agent according to claim 9, wherein the substance inhibits CXCR4 in antagonistic competition with SDF-1.

10 12. The therapeutic agent according to claim 9, wherein the substance inhibits SDF-1 from binding to CXCR4 by binding to SDF-1.

15 13. The therapeutic agent according to claim 11, wherein the substance is one selected from the group consisting of a SDF-1-like protein, a fused protein of the foregoing protein with another peptide or polypeptide, a partial peptide of SDF-1, and a low molecular weight compound having a structure similar to a binding site of SDF-1.

20 14. The therapeutic agent according to claim 12, wherein the substance is one selected from the group consisting of an anti-SDF-1 antibody, a fragment of said antibody possessing the activity of the anti-SDF-1 antibody, a fused protein possessing binding activity to SDF-1, a substance that induces a structural change in SDF-1, and a low molecular weight
25 compound capable of binding to the CXCR4-binding site of SDF-1.

15. The therapeutic agent according to claim 10, wherein the substance inhibits CXCR4 in antagonistic competition with CXCR4 for binding to SDF-1.

16. The therapeutic agent according to claim 10, wherein the substance inhibits SDF-1 from binding to CXCR4 by binding to CXCR4.

17. The therapeutic agent according to claim 15, wherein the substance is one selected from the group consisting of a soluble CXCR4 that antagonizes CXCR4 in the inhibition, a protein having a CXCR4-like structure, a fused protein of the foregoing protein with another peptide or polypeptide, a partial peptide of CXCR4, and a low molecular weight compound having a structure similar to a binding site of SDF-1.

18. The therapeutic agent according to claim 16, wherein the substance is one selected from the group consisting of an anti-CXCR4 antibody, a fragment of said antibody possessing the activity of anti-CXCR4 antibody, a fused protein possessing binding activity to CXCR4, a substance that induces a structural change in SDF-1, and a low molecular weight compound capable of binding to the SDF-1-binding site of CXCR4.

19. The therapeutic agent according to claim 6, wherein the substance is an inhibitor of a signaling system located downstream of a G protein-coupled protein and is one selected from the group consisting

of a MAPK cascade inhibitor, a ^{Phospholipase} ~~phospholipase~~ C (PLC) inhibitor, and a PI3 kinase inhibitor.

20. The therapeutic agent according to claim 7, wherein the substance is a substance that causes apparent disappearance of CXCR4 from cells by acting ^{on a cell} ~~on cell~~ membrane to vary fluidity thereof and to cause disappearance of CXCR4 from the cell membrane.

21. The therapeutic agent according to claim 7, wherein the substance is a substance that inhibits the ~~very~~ expression of CXCR4 and is one selected from the group consisting of an antigene, an antisense polynucleotide, an antisense RNA expressed by an antisense vector, a ribozyme, and an inhibitor against the expression control site of CXCR4.

22. The therapeutic agent according to claim 8, wherein the substance is an antisense ^{Polynucleotide} ~~for the~~ ^{Capable} ~~of inhibiting the~~ inhibition of expression of SDF-1.

23. The therapeutic agent according to claim 8, wherein the substance ^{inhibits} ~~shows inhibition against~~ the expression control site of SDF-1.

24. A method for suppressing vascularization comprising using a substance that inhibits the action ^{to a mammal in need thereof} due to CXCR4.

25. A method for treating a solid cancer ^{administering} comprising ~~using~~ a substance that inhibits the action ^{to a mammal in need thereof} due to CXCR4.

26. A method for treating a disease

pathologically caused by neovascularization comprising
~~administering~~
~~using~~ a substance that inhibits the action due to
to a mammal in need thereof
CXCR4.

5

27. A method for repairing a tissue comprising

~~administering~~
~~using~~ a substance that inhibits the action due to
to a mammal in need thereof
CXCR4.

add
C3

09646735-021501
T09646735-021501